The U.S. Food and Drug Administration recently granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma. Tudriqev is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Gastroparesis is a condition where the stomach empties food much more slowly than it should, even though there isn’t a blockage. As food sits in the stomach longer, people may experience nausea, vomiting, bloating, feeling full after just a few bites, abdominal pain, and sometimes weight loss.
According to the Centers for Disease Control and Prevention (CDC), COVID-19 is still circulating across the United States, and the agency continues to monitor activity closely. While the virus has settled into a more predictable seasonal pattern, the CDC does not rely on case counts alone to determine whether the country is experiencing a surge. Instead, it tracks several indicators, including wastewater levels, emergency department visits, hospitalizations, laboratory testing, and the variants that are circulating.
Most people have heard of bacterial infections that are resistant to antibiotics, but fewer know about Candida auris (C. auris)—a fungus that has become an increasing public health concern. Since it was first identified in 2009, C. auris has spread to healthcare facilities around the world and is now considered an urgent antimicrobial resistance threat by the...
For years, lowering LDL cholesterol—often called “bad cholesterol”—has been one of the main ways to reduce the risk of heart attack and stroke. While LDL cholesterol is still very important, researchers now know that it is not the only cholesterol-related factor that affects heart health.
What Is Gastroparesis? August is Gastroparesis Awareness Month, an opportunity to raise awareness about a digestive disorder that affects an estimated 5 million people in the United States. Although gastroparesis has long been recognized by gastroenterologists, it has recently gained public attention because of the widespread use of GLP-1 receptor agonists for...